Receptors in the management of breast cancer.
Assay of breast cancers for oestrogen receptors helps to select advanced cases (about 30%) who will benefit from milder (endocrine) therapy, and, in early disease, gauge overall survival and likelihood of benefit from adjuvant endocrine therapy. A reliable immunocytochemical assay for receptor, now available, should extend the usefulness of such measurements.